Karyopharm Therapeutics Inc
$ 10.09
0.20%
25 Feb - close price
- Market Cap 184,724,000 USD
- Current Price $ 10.09
- High / Low $ 10.38 / 9.95
- Stock P/E N/A
- Book Value -16.00
- EPS -17.93
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -8.91 %
- 52 Week High 10.99
- 52 Week Low 3.51
About
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.
Analyst Target Price
$15.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-05 | 2025-08-11 | 2025-05-12 | 2025-02-19 | 2024-11-05 | 2024-08-06 | 2024-05-08 | 2024-02-29 | 2023-11-02 | 2023-08-02 | 2023-05-04 |
| Reported EPS | -2.2271 | -3.82 | -4.07 | -2.77 | -3.6 | -3.9 | 0.15 | -0.32 | -0.36 | -0.3 | -0.29 | -0.3 |
| Estimated EPS | -2 | -2.21 | -3.91 | -3.09 | -4.03 | -3.92 | -0.3 | -0.33 | -0.31 | -0.28 | -0.34 | -0.37 |
| Surprise | -0.2271 | -1.61 | -0.16 | 0.32 | 0.43 | 0.02 | 0.45 | 0.01 | -0.05 | -0.02 | 0.05 | 0.07 |
| Surprise Percentage | -11.355% | -72.8507% | -4.0921% | 10.356% | 10.67% | 0.5102% | 150% | 3.0303% | -16.129% | -7.1429% | 14.7059% | 18.9189% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KPTI
2026-02-24 02:21:30
Karyopharm Therapeutics (NASDAQ:KPTI) shareholders have approved a plan to nearly double the company's total authorized shares from 58,333,333 to 111,000,000, and common shares from 53,333,333 to 106,000,000. This decision was made at a virtual special meeting held on February 18, 2026, and also included approval of a contingency adjournment to solicit additional proxies if needed. Final vote results are pending disclosure in a Form 8-K.
2026-02-19 21:26:37
Karyopharm Therapeutics (KPTI) shareholders approved a significant increase in the company's authorized capital stock, raising the total from 58,333,333 to 111,000,000 shares and common stock from 53,333,333 to 106,000,000 shares. This decision, made on February 18, 2026, expands the company's ability to issue new shares for future financing or strategic moves. Spark, TipRanks’ AI Analyst, currently rates KPTI as Neutral due to weak financial fundamentals, despite some constructive technical momentum and a catalyst-driven earnings outlook.
2026-02-18 16:27:55
Wall Street analysts project Karyopharm Therapeutics (KPTI) could see a 56.1% upside based on a mean price target of $14.67, despite the stock gaining 58% in the past four weeks. While analyst price targets can be overly optimistic, the consensus around higher earnings estimates and KPTI's Zacks Rank #2 (Buy) suggest a potential upside. Investors should, however, consider price targets with skepticism and use them as a starting point for further research.
2026-02-18 13:27:55
HC Wainwright has reaffirmed its "Buy" rating for Karyopharm Therapeutics (NASDAQ:KPTI), setting a price target of $15, indicating a potential 59.6% upside. Other analysts also maintain largely positive ratings for the biopharmaceutical company, which specializes in developing drugs targeting nuclear export protein XPO1. Karyopharm recently reported Q4 EPS of ($2.23) and revenue of $34.08 million, both surpassing analyst expectations.
2026-02-13 23:57:59
Karyopharm Therapeutics (KPTI) recently held its Q4 earnings call, revealing a precarious financial situation despite promising upcoming Phase III data for myelofibrosis and endometrial cancer. The company is facing a tight cash runway, significant GAAP losses, and higher interest costs, which heighten the importance of positive clinical readouts in early to mid-2026. While XPOVIO's revenue saw modest growth, Karyopharm's liquidity is projected to fund operations only into Q2 2026, making strong trial results and successful financing crucial for its future.
2026-02-13 23:57:59
Karyopharm Therapeutics (KPTI) reported a Q4 FY 2025 net loss of US$102.2 million and a trailing twelve-month (TTM) net loss of US$196.0 million on US$146.1 million in revenue. Despite analyst expectations for revenue growth (30.2% annually) and eventual margin improvement, the company faces significant financial strain, including less than one year of cash runway and negative shareholders' equity, raising concerns about funding risks and dilution. While its P/S ratio appears low compared to peers, the substantial TTM losses indicate that any re-rating would depend heavily on future revenue growth translating into significantly reduced losses.
